IHH 5225 Share Price
RM5.48
52 Weeks Range : 4.85 - 5.79
4.3/10
(Expert Score)
Product is rated as #11 in category BM Health Care
PROS:
- Very High Trading Value
CONS:
- Poor Income Near Future
- Very Low Price-to-Tangible
- High Gearing Ratio
klse: IHH Healthcare Bhd
Corporate Information
Board : Main
Shariah : Shariah Compliant
Sector : Ringgit Consumer Healthcare
Address: Level 11 Block A,Pantai Hospital Kuala Lumpur,8, Jalan Bukit Pantai, , 59100, Kuala Lumpur
Contact: +603-2298 9898
Website: https://www.ihhhealthcare.com/
Corporate Background
IHH Healthcare Bhd provides healthcare services. The Company operates hospitals as well as medical centers, clinics and ancillary healthcare businesses across multiple countries, including Singapore, Malaysia, Turkey, The Peoples Republic of China, India, Hong Kong, Vietnam, Macedonia and Brunei.
Genaral Info: IHH 5225
|
Result
Quarter Report History
| Date | Revenue,k | PBT,k | Net Profit,k |
|---|---|---|---|
| 01/06/21 | 3,945,780 | 586,497 | 375,621 |
| 26/02/21 | 3,765,987 | 660,927 | 419,358 |
| 26/11/20 | 3,518,331 | 395,969 | 309,952 |
| 27/08/20 | 2,565,110 | -232,032 | -120,642 |
| 29/06/20 | 3,555,176 | -257,357 | -319,786 |
| 28/02/20 | 3,836,099 | 195,731 | 40,630 |
| 29/11/19 | 3,788,364 | 394,263 | 236,342 |
| 30/08/19 | 3,645,335 | 265,644 | 184,994 |
| 30/05/19 | 3,642,687 | 187,086 | 89,510 |
| 27/02/19 | 3,165,348 | 812,878 | 509,417 |
| 27/11/18 | 2,840,915 | -316,711 | -104,071 |
| 28/08/18 | 2,659,716 | 166,425 | 165,106 |
Fundamental
Fundamental Analysis
| Last 4 Quarter Revenue (RM’000) | 13,795,208 |
|---|---|
| Last 4 Quarter Net Profit (RM’000) | 1,005,393 |
| Last 4 Quarter EPS (sen) | 10.2 |
| Last 4 Quarter PER | 47.85 |
| Last 4 Quarter Dividend (sen) | 4.00 |
| Last 4 Quarter Dividend Yield (%) | 0.73 |
| Net Tangible Assets (RM) | 2.48 |
| Goodwill (RM) | 14,113,540 |
| Cash (RM’000) | 4,610,000 |
| Debt (RM’000) | 13,790,000 |
| Total Debt (RM’000) | 19,870,000 |
| Net Assets (RM’000) | 21,740,000 |
| Current Ratio | 1.31 |
| Quick Ratio | 1.22 |
| Cash Ratio | 0.82 |
Technical
Technical Analysis
| MACD (26 vs 12) | – |
|---|---|
| Exponential Moving Average 5 | 5.371 |
| Exponential Moving Average 20 | 5.351 |
| Exponential Moving Average 90 | 5.347 |
| Relative Strength Index 14 | 0.59 |
| Stochastic %D 3 | 0.69 |
| Stochastic %K 14 | 0.70 |
4 reviews for IHH 5225
Show all
Most Helpful
Highest Rating
Lowest Rating
BURSA MALAYSIA –
The Group reported a 28% and 64% quarter-on-quarter decrease in revenue and EBITDA respectively as a result of the COVID-19 pandemic.
BURSA MALAYSIA –
The Group reported a 7% and 19% quarter-on-quarter decrease in revenue and EBITDA respectively as a result of the COVID-19 pandemic in Q1 2020. EBITDA decreased from a high base when the Group recorded RM11.4 million revaluation gain on PLife REIT’s investment properties in Q4 2019.
REMUNERATION STUDY –
In Financial Year End 2019, the directors’ remuneration was 63.03 million. It was slightly low compared to average in listed companies, considering the employees’ remuneration of 5371.5 million and auditor’s remuneration of 1254 thousands
INVESTING MALAYSIA –
21 JAN 20 – London Stock Exchange (LSE)-listed Symphony International Holding Ltd has fully exited its investment in IHH Healthcare Bhd.
INVESTING MALAYSIA –
IHH (6 JAN 20) IHH shares took a hit in early trading today as geopolitical tension in the Middle East soared following the killing of an Iranian general in Baghdad, Iraq last week.
Investing Malaysia –
Average investing volume for IHH Healthcare Bhd in the past three months in stock market was 4502.7k lots
Investing Malaysia –
IHH gets a score of 7.28 in our equity and assets quality test based on current share price of RM5.74
Investing Malaysia –
IHH Healthcare Bhd gets a score of 14.89 in our stability test after the balance sheet, money statement study
Investing Malaysia –
Stock code of 5225 in Bursa Malaysia declared adjusted 0.52% dividend yield in past few years
Investing Malaysia –
IHH is estimated to have a profit consensus of 1123.43 millions, with an adjusted market capitalization of 49134.35 millions
REMUNERATION STUDY –
In Financial Year End 2018, the directors’ remuneration was 48.64 million. It was slightly low compared to average in listed companies, considering the employees’ remuneration of 4538.1 million and auditor’s remuneration of 1212 thousands